Taiwan Covid-19 Vaccines May Be Late For US Emergency Testing

Taiwan Covid-19 Vaccines May Be Late For US Emergency Testing


Both companies have completed Phase 2 clinical trials of their vaccines and, according to officials from the two companies, are aiming for EUA approval from local regulators, hopefully in the next few months to commercialize their vaccines.

Read more on Taiwan Covid-19 Vaccines May Be Late For US Emergency Testing…


Both companies have completed Phase 2 clinical trials of their vaccines and, according to officials from the two companies, are aiming for EUA approval from local regulators, hopefully in the next few months to commercialize their vaccines.

However, their vaccines could only be marketed in Taiwan as the US FDA has stated it may no longer issue EUAs for new vaccine candidates, warned Su Ih-jen, former director general of the Centers for Disease Control.

“The US outbreak has stabilized and vaccines developed by American companies are in abundance, which means the US FDA is not required to provide EEA for vaccine candidates from other countries,” he said.

Su said a halt to EUA testing by the US FDA would make it more difficult for locally developed vaccines to make it onto the world market, especially as a number of international branded products have already completed their third and final clinical trials and are ready for full trials to be obtained for use in their home countries.

“But the local vaccines have only just completed Phase 2 clinical trials and have a long way to go before Phase 3 trials,” said Su. He added that if fully proven global branded products came into the Taiwanese market, local brands would face stiff competition and people would be more likely to choose foreign vaccines.

The US FDA said in late May that it would be reviewing and processing EUA applications for. could refuse

for the remainder of the pandemic, if a company hadn’t already started talks.

Currently three

have emergency clearance from the US FDA. These include messenger RNA-based vaccines from Pfizer Inc and Moderna, and an adenovirus-based vaccine from Johnson & Johnson.

Queues at Taiwan Covid-19 testing site as island battles escalate in cases

01:16

Queues at Taiwan Covid-19 testing site as island battles escalate in cases

According to, Novavax Inc has held discussions with regulators and does not expect it to seek regulatory approval for its Covid-19 inclusion in the US, UK and Europe until the third quarter of 2021.

Canadian developer Medicago said it was in talks with the FDA about an EUA for its herbal Covid-19 vaccine candidate, which will be improved by a GlaxoSmithKline treatment.

UK-based AstraZeneca has also discussed plans for its Covid-19 vaccine with US officials. However, The Wall Street Journal Earlier this month reported that it is considering skipping the U.S. emergency permit in favor of the more time-consuming application for a full license to sell the shot.

.

COMMENTS